Altimmune’s Fatty Liver Candidate Faces Differentiation Doubts

Trucchio sees 48-week data as key for Phase 3 progress, while William Blair questions drug’s impact on fibrosis and weight loss at 24 weeks.

Latest Ratings for ALT

DateFirmActionFromTo Jun 2021B. Riley SecuritiesMaintainsBuy Jun 2021JMP SecuritiesMaintainsMarket Outperform Jun 2021HC Wainwright & Co.MaintainsBuy

View More Analyst Ratings for ALT

View the Latest Analyst Ratings

read more